Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay
Hari Sankaran, Yuri Kotliarov, Yingdong Zhao, Lyndsay N. Harris, James V. Tricoli, Stanley R. Hamilton, Sarah M. Temkin, Chris Karlovich, Ting-Chia Chang, Victoria Wang, Robert J. Gray, Zihan Wei, Sarah J. Shin, Nita L. Seibel, Biswajit Das, Brent Coffey, David Patton, Ming-Chung Li, Jessica Li, Ana F. Best, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Keith T. Flaherty, Alice P. Chen, Peter J. O'Dwyer, Lisa M. McShanePURPOSE
Motivated by the rising incidence of cancers at younger ages, this study compares tumor genomic alterations between adolescents and young adults (AYAs; 18-39 years) and non-AYAs (40 years and older) and explores the relationship with continuous age in patients with relapsed/refractory ovarian, breast, and colorectal cancers accrued to the NCI-MATCH trial.
METHODS
Tumor genomic profiles generated by a next-generation sequencing 143-gene panel (NCI-MATCH assay, v2) were analyzed for association with age (AYA/total: 21/455 ovarian, 27/576 breast, 43/759 colorectal cancers). For each gene, AYA and non-AYA DNA alteration proportions were compared (Fisher exact test) and alteration association with continuous age (logistic regression) was evaluated (false discovery rate‑adjusted
RESULTS
No significant AYA versus non-AYA differences were observed in the prevalence of gene mutations (single nucleotide variant [SNV]/indel). A significant association of gene amplification with AYAs (odds ratio [OR], 95% CI) was
CONCLUSION
Comparing AYAs with non-AYAs among patients having relapsed/refractory disease, no significant differences in SNV/indel prevalence were observed, but